Daiichi Sankyo Company, Limited

Fumihito Muro

Nobuo Machinaga

Jun Chiba

Jun Watanabe

Atsushi Nakayama

Shin Iimura

Yoshiyuki Yoneda

Hiroshi Yuita

Hideko Hoh

To provide a novel compound or an isotope thereof or a pharmaceutically acceptable salt thereof having S1P lyase inhibitory capacity and inducing the decrease in number of lymphocytes, and a pharmaceutical composition containing these as active ingredients. A compound represented by the general formula (I): or the general formula (II): or an isotope thereof or a pharmaceutically acceptable salt thereof.

Imidazole derivative

There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally. A compound represented by the following formula (I): wherein Rrepresents a hydrogen atom or a C1-8 alkyl group; Rrepresents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, or a benzyloxy group which may be substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group which may be substituted; R, Rand Reach independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and Arepresents a nitrogen atom or C&#x2014;R(wherein Rrepresents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group),

VLA-4 inhibitory drug

Growing community of inventors

Tokyo, Japan

Fumihito Muro